Pulmonx (LUNG) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access LUNG Annual Cash Flow →
From Pulmonx through Jun 30 2025, changes in Jun 30 2026's operating cash flow provide insight into underlying business performance trends.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2026)
6 Months
(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-23.73
Depreciation & amortization0.84
Amortization of Other Assets0.18
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Other Restructuring Costs0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase1.36
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation7.83
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction-0.08
Fair Value Adjustment Of Derivative Liabilities-
Write Off Of Deferred Debt Issuance Cost-
Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost-
Operating Lease Right Of Use Asset Amortization Expense0.42
Increase Decrease In Operating Lease Liability-0.33
Increase Decrease In Contract With Customer Liability0.01
Income taxes0.00
Gain (Loss) on Sale of Properties0.00
Increase (Decrease) in Accounts Receivable0.30
Increase (Decrease) in Accounts Payable0.77
Increase (Decrease) in Accrued Liabilities-0.38
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets-0.49
Other Working Capital0.05
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-1.97
Discontinued operations0.00
Net Cash flow from Operating Activities-15.31
Investing Activities
Capital Expenditures-0.01
Sale of Capital Items0.00
Proceeds from Maturities, Prepayments and Calls of Short-term Investments0.00
Payments to Acquire Available-for-sale Securities, Debt0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net-0.04
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.01
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-0.26
Long-term debt - borrowings1.79
Long-term debt - repayments-0.05
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.04
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Issuance Of Temporary Equity-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents70.01
Issuance Of Derivative Instrument For Convertible Debt-
Debt Conversion Converted Instrument Amount-
Right Of Use Asset Recorded Upon Adoption Of Accounting Standards Update-
Right Of Use Asset Obtained In Exchange For Operating Lease Liability-
Payments Of Debt Fees-
Restricted Cash0.26
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities1.51
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-15.32
Total Cash Flow-13.91
4 historic quarters locked

Sign in to unlock the full Pulmonx cash flow history.

About Pulmonx Corp Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001127537-26-000039

Figures are derived from filed reports and may be restated. Historical data is subject to revision.